Correlations of acute myocardial infarction complicated by cerebral infarction with insulin resistance, adiponectin and HMGB1

摘要

OBJECTIVE: To investigate the correlations of acute myocardial infarction (AMI) complicated by cerebral infarction with insulin resistance, adiponectin and high-mobility group box 1 (HMGB1). PATIENTS AND METHODS: A total of 326 AMI patients receiving percutaneous coronary intervention (PCI) were selected as the research objects. They were divided into cerebral infarction group (n=24) and non-cerebral infarction group (n=302) based on their complication of cerebral infarction. In addition, 165 healthy people were enrolled as control group. Changes in the levels of HMGB1, adiponectin, fasting insulin (FINS), insulin sensitive index (ISI), insulin resistance, N-terminal pro-B-type natriuretic peptide (NT-proBNP), C-reactive protein (CRP), interleukin-6 (IL-6), myocardial infarction markers and coagulation function indexes were compared among the three groups. Correlations among those indexes were analyzed. RESULTS: AMI patients had higher levels of HMGB1, FINS, homeostasis model assessment of insulin resistance (HOMA-IR), ISI, creatine kinase isoenzyme (CK-MB), cardiac troponin I (cTnI), prothrombin time (PT), CRP and IL-6 than those in healthy participates, especially in those complicated with cerebral infarction. Conversely, levels of adiponectin, myoglobin (Mb), activated partial thromboplastin time (APTT), antithrombin III (AT-III), activated coagulation time (ACT) and NT-proBNP were the lowest in cerebral infarction group, and highest in control group (p0.05). AMI complicated with cerebral infarction was negatively correlated with the levels of AT-III and adiponectin, but positively associated with the levels of NT-proBNP, HOMA-IR and HMGB1 (p0.05). CONCLUSIONS: AMI complicated with cerebral infarction has negative correlations with the levels of AT-III and adiponectin, but positively associated with the levels of NT-proBNP, HOMA-IR and HMGB1, possessing certain clinical significance in AMI treatment.